| Theme | Amyloid-Related Bone and Joint Derangements -- Clinical Diagnosis and Treatment | |
|---|---|---|
| Title | Selective extracorporeal removal of beta2-microglobulin with adeorbent column in dialysis-related amyloidosis (DRA) | |
| Publish Date | 1997/08 | |
| Author | Ryoichi Nakazawa | Tokatsu Clinic Hospital, Department of Nephrology |
| [ Summary ] | The cause of DRA has been proven to be the undesirable accumulation of beta2-microglobulin (beta2-MG) in serum. In order to eliminate beta2-MG from circulating blood, a beta2-MG selective adsorbent for direct hemoperfusion (DHP) was developed. A DHP column (BM-0l; LixelleTM) containing 350 ml of the adsorbent, was connected with a dialyzer in series and clinical trials were conducted. Plasma clearances for beta2-MG were calculated to be 45.4+-4.1 (HD), 49.1+-7.8 (HDF ; 5l), 89.4 +-9.2 (DHP + HD), and 88.7 +-9.8 (HD+DHP) ml/min. With DHP therapy, improvements in ADL, joint pain, joint mobility, and stiffness were observed. It can be concluded that BM-01 is a useful device for eliminating beta2-MG from dialysis patients and that this selective adsorption therapy may delay the progression of DRA. |
|